阿普斯特中国上市了吗？

It was approved by the U.S. Food and Drug Administration (FDA) on September 23, 2014 for the treatment of adult patients with moderate to severe plaque psoriasis (also known as Plaque Psoriasis) who are suitable for phototherapy and systemic therapy.

Apremilast is the first and only PDE4 inhibitor approved by the FDA for the treatment of plaque psoriasis; the clinical efficacy of Apremilast:

A phase IIb, multicenter, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of apremilast in the treatment of plaque psoriasis. Patients older than 18 years with plaque psoriasis were randomized 1:1:1:1 to receive apremilast 10 mg (n = 89), 20 mg (n = 87), 30 mg (n = 88), or placebo (n = 88). After 16 weeks of treatment, the proportion of patients whose Psoriasis Area and Severity Index (PASI-75) was reduced by at least 75% from baseline was 5 (6%) in the placebo group, 10 (11%) in the 10 mg group, 25 (29%) in the 20 mg group, and 36 (41%) in the 30 mg group. There was no significant difference between the 10 mg group and the placebo group, and there was no significant difference between the 20 mg group and the 30 mg group. Compared with the placebo group, the difference was statistically significant. The vast majority of adverse reactions (96%) were mild to moderate and included nausea, diarrhea, headache, gastroenteritis, or dyspepsia. Trials have shown that Apremilast is safe, effective and well tolerated in the treatment of plaque psoriasis.

Has Apremilast been launched in China?

It has not been officially launched in China yet. If domestic patients need Apremilast, they can purchase the version available abroad. For specific information about Apremilast, you can always consult Medical Companion Travel!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: